Aflibercept biosimilar - Alteogen/Kissei

Drug Profile

Aflibercept biosimilar - Alteogen/Kissei

Alternative Names: Eylea® Biosimilar - Alteogen

Latest Information Update: 27 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alteogen; Kissei Pharmaceutical
  • Class Antineoplastics; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 27 Apr 2017 Preclinical trials in Wet age-related macular degeneration in Japan (Intravitreous) (Alteogen pipeline, April 2017)
  • 27 Apr 2017 Preclinical trials in Wet age-related macular degeneration in South Korea (Intravitreous) (Alteogen pipeline, April 2017)
  • 12 Feb 2014 Early research in Wet age-related macular degeneration in Japan (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top